ArticleCureus2025
Sodium Valproate Versus Levetiracetam in Pediatric Generalized Epilepsy: A Comparative Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Galangin mitigates letrozole-induced polycystic ovary syndrome in rats by restoring PI3K/pAKT/PTEN signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Is Levetiracetam as Good as Valproate for Treatment of Childhood Epilepsy?Indian journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim and objectives Generalized epilepsy impacts a significant portion of the pediatric population. Safety and efficacy are key considerations in the treatment of epileptic seizures in children. New generation anti-seizure medications (ASMs) promise to fulfil this need. Thus, this study was planned to compare the efficacy, safety, and tolerability of sodium valproate (VPA) and levetiracetam (LEV) in children with generalized epilepsy. Material and methods A total of 211 pediatric patients aged 2-14 years with generalized seizures were prospectively enrolled and randomized either to receive VPA (n=107) or LEV (n=104) as per the recommended protocol up to six months. Seizure-free duration and seizure-free outcomes were assessed at six months. Adverse events, drug tolerability, and compliance were recorded. The data was statistically analyzed. Results Of the 211 participants, 187 completed the study (VPA group: 94; LEV group: 93). The two groups were comparable for demographic and clinical profiles at the time of start of treatment. The seizure-free duration was significantly longer in the VPA group (153.61 ± 53.12 days) compared to the LEV group (135.82 ± 68.79 days). Seizure-free outcome rates at three and six months were 88.3% and 79.8% in the VPA group, and 81.7% and 66.7% in the LEV group, respectively, with a statistically significant difference between the groups at six months. The VPA group had significantly shorter mean hospital need (1.68 days) as compared to the LEV group (2.82 days). Post-treatment increase in SGPT was significantly higher in the VPA group. Nausea/vomiting and weight gain were significantly more common in the VPA group, while behavioral adverse effects were significantly more common in the LEV group. Conclusion VPA was found to be more efficacious in controlling seizures in children with generalized epilepsy than LEV. With respect to safety, both treatments had specific issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.